SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.01B
Enterprise Value 3
601.83M
Trailing P/E
N/A
Forward P/E 1
-6.49
PEG Ratio (5 yr expected) 1
0.35
Price/Sales (ttm)
13.22
Price/Book (mrq)
2.26
Enterprise Value/Revenue 3
7.92
Enterprise Value/EBITDA 6
-5.49

Trading Information

Stock Price History

Beta (3Y Monthly) 2.29
52-Week Change 3-32.15%
S&P500 52-Week Change 310.73%
52 Week High 314.53
52 Week Low 36.26
50-Day Moving Average 39.57
200-Day Moving Average 310.60

Share Statistics

Avg Vol (3 month) 31.22M
Avg Vol (10 day) 31.35M
Shares Outstanding 5115.67M
Float 115.55M
% Held by Insiders 10.39%
% Held by Institutions 157.39%
Shares Short (Sep 30, 2019) 417.55M
Short Ratio (Sep 30, 2019) 416.89
Short % of Float (Sep 30, 2019) 415.25%
Short % of Shares Outstanding (Sep 30, 2019) 415.17%
Shares Short (prior month Aug 30, 2019) 416.35M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -136.73%
Operating Margin (ttm)-147.75%

Management Effectiveness

Return on Assets (ttm)-10.79%
Return on Equity (ttm)-25.10%

Income Statement

Revenue (ttm)76.02M
Revenue Per Share (ttm)0.72
Quarterly Revenue Growth (yoy)-18.10%
Gross Profit (ttm)-30.41M
EBITDA -109.58M
Net Income Avi to Common (ttm)-103.94M
Diluted EPS (ttm)-0.99
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)441.1M
Total Cash Per Share (mrq)3.81
Total Debt (mrq)44.03M
Total Debt/Equity (mrq)9.88
Current Ratio (mrq)5.63
Book Value Per Share (mrq)3.85

Cash Flow Statement

Operating Cash Flow (ttm)-151.87M
Levered Free Cash Flow (ttm)-103.51M